Active	Status	Sponsor type	Region	Phase	Filter
8 Active 6 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Böhmig, Georg
NCT05021484 / 2021-000545-40: Felzartamab in Late Antibody-Mediated Rejection	Completed	2	22	Europe	Felzartamab, MOR202, CD38 monoclonal antibody, Placebo, 0.9% Saline	Farsad Eskandary, Charite University, Berlin, Germany, University of Alberta, HI-Bio	Antibody-mediated Rejection	03/24	03/24
NCT04711850 / 2020-004777-49: An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR	Terminated	N/A	18	Europe	Imlifidase, IdeS, HMED-IdeS	Hansa Biopharma AB	Kidney Transplant Rejection	03/23	03/23
Wahrmann, Markus
NCT05021484 / 2021-000545-40: Felzartamab in Late Antibody-Mediated Rejection	Completed	2	22	Europe	Felzartamab, MOR202, CD38 monoclonal antibody, Placebo, 0.9% Saline	Farsad Eskandary, Charite University, Berlin, Germany, University of Alberta, HI-Bio	Antibody-mediated Rejection	03/24	03/24
Oberbauer, Rainer
PAES, NCT05369975: Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts	Recruiting	3	225	Europe, RoW	Imlifidase, IdeS, HMED-IdeS, Normal Transplantation Routine	Hansa Biopharma AB	Kidney Transplantation in Highly Sensitized Patients	12/24	12/24
Regele, Heinz
NCT05021484 / 2021-000545-40: Felzartamab in Late Antibody-Mediated Rejection	Completed	2	22	Europe	Felzartamab, MOR202, CD38 monoclonal antibody, Placebo, 0.9% Saline	Farsad Eskandary, Charite University, Berlin, Germany, University of Alberta, HI-Bio	Antibody-mediated Rejection	03/24	03/24
Eskandary, Farsad
NCT05021484 / 2021-000545-40: Felzartamab in Late Antibody-Mediated Rejection	Completed	2	22	Europe	Felzartamab, MOR202, CD38 monoclonal antibody, Placebo, 0.9% Saline	Farsad Eskandary, Charite University, Berlin, Germany, University of Alberta, HI-Bio	Antibody-mediated Rejection	03/24	03/24